



## Dissecting the Immunological Landscape of Human Malignancies

Guest Editor:

**Prof. Dr. Sergio Rutella**

College of Science and  
Technology, Clifton Campus,  
Nottingham Trent University,  
Nottingham NG11 8NS, UK

Deadline for manuscript  
submissions:

**closed (31 December 2017)**

### Message from the Guest Editor

Dear Colleagues,

This Special Issue will focus on novel tools, which are being developed to analyse the diversity of immune genes, proteins, cells and pathways in the tumour microenvironment. Powerful technologies, such as genome-wide association studies (GWAS), multiplexed immunohistochemistry, high-dimensional blood profiling of immune cells by flow cytometry and mass cytometry, are increasingly being integrated to assess immune competence and the likelihood of patients to respond to immunotherapy. A broader understanding of baseline immunity (the “immunoscore”), both in the periphery and in the tumour microenvironment, and of immune escape mechanisms is likely to expedite the identification of biomarkers that are predictive of clinical outcome and to foster the clinical implementation of a more refined and personalised approach to immune-based interventions.

Prof. Sergio Rutella

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)